CP-809101 is a drug which acts as a potent and selective 5-HT2C receptor agonist.[1] It had promising results in animal models of obesity and psychosis, but associated with genotoxicity which means that future use will be restricted to scientific research applications only.[2][3]

CP-809101
Clinical data
ATC code
  • None
Identifiers
  • 2-[(3-Chlorophenyl)methoxy]-6-(1-piperazinyl)pyrazine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H17ClN4O
Molar mass304.78 g·mol−1
3D model (JSmol)
  • C2CNCCN2c(n3)cncc3OCc(c1)cccc1Cl
  • InChI=1S/C15H17ClN4O/c16-13-3-1-2-12(8-13)11-21-15-10-18-9-14(19-15)20-6-4-17-5-7-20/h1-3,8-10,17H,4-7,11H2 ☒N
  • Key:PCWGGOVOEWHPMG-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

References

edit
  1. ^ Strong PV, Greenwood BN, Fleshner M (May 2009). "The effects of the selective 5-HT(2C) receptor antagonist SB 242084 on learned helplessness in male Fischer 344 rats". Psychopharmacology. 203 (4): 665–75. doi:10.1007/s00213-008-1413-3. PMID 19037632. S2CID 24956531.
  2. ^ Siuciak JA, Chapin DS, McCarthy SA, Guanowsky V, Brown J, Chiang P, Marala R, Patterson T, Seymour PA, Swick A, Iredale PA (February 2007). "CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity". Neuropharmacology. 52 (2): 279–90. doi:10.1016/j.neuropharm.2006.07.024. PMID 16949622. S2CID 46489320.
  3. ^ Kalgutkar AS, Dalvie DK, Aubrecht J, Smith EB, Coffing SL, Cheung JR, Vage C, Lame ME, Chiang P, McClure KF, Maurer TS, Coelho RV, Soliman VF, Schildknegt K (June 2007). "Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation" (PDF). Drug Metabolism and Disposition. 35 (6): 848–58. doi:10.1124/dmd.106.013649. PMID 17344339. S2CID 29863246. Archived from the original (PDF) on 2019-02-25.